Federal: HR10336

Bill Summary

US HR 10336, the Dietary Supplement Innovation Act, amends the Federal Food, Drug, and Cosmetic Act to clarify and create exceptions to the FDA's "drug preclusion" rule, which currently prevents ingredients from being used in dietary supplements if they have been approved as pharmaceuticals or are undergoing Phase 2 or Phase 3 clinical trials. The bill protects supplements containing ingredients that were legally marketed before drug investigation began, ingredients whose drug development has been inactive for at least seven years, or substances used only for food safety purposes. It requires the FDA to evaluate meaningful differences in dosage, concentration, and delivery method between pharmaceutical drugs and supplement versions when determining violations. The legislation also grants companies the right to immediately challenge FDA warning letters in federal court, placing the burden of proof on the government to demonstrate a violation occurred.

Why It Matters to MAHA

This bill directly advances MAHA's core commitment to health freedom and patient autonomy by preventing the FDA from using overly broad drug preclusion rules to restrict access to innovative supplement ingredients. The measure protects consumer choice by allowing safe ingredients that predate drug approvals or have abandoned development timelines to remain available in supplements, reflecting the principle that regulatory barriers should not arbitrarily block proven, accessible treatments. By requiring the FDA to consider meaningful pharmacological differences and giving companies a fair legal process to challenge agency assertions, the bill enhances transparency and ensures regulatory decisions are evidence-based rather than categorically restrictive. This legislation recognizes that supplements and pharmaceuticals serve different markets and that consumers should retain access to both as part of their health autonomy.